134 related articles for article (PubMed ID: 16840186)
1. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies.
Friedrichs B; Siegel S; Andersen MH; Schmitz N; Zeis M
Leuk Lymphoma; 2006 Jun; 47(6):978-85. PubMed ID: 16840186
[TBL] [Abstract][Full Text] [Related]
2. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
3. HLA-B35-restricted immune responses against survivin in cancer patients.
Reker S; Becker JC; Svane IM; Ralfkiaer E; Straten PT; Andersen MH
Int J Cancer; 2004 Mar; 108(6):937-41. PubMed ID: 14712500
[TBL] [Abstract][Full Text] [Related]
4. Survivin--a universal tumor antigen.
Andersen MH; thor SP
Histol Histopathol; 2002 Apr; 17(2):669-75. PubMed ID: 11962766
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
7. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
Siegel S; Wagner A; Schmitz N; Zeis M
Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
[TBL] [Abstract][Full Text] [Related]
8. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.
Casati C; Dalerba P; Rivoltini L; Gallino G; Deho P; Rini F; Belli F; Mezzanzanica D; Costa A; Andreola S; Leo E; Parmiani G; Castelli C
Cancer Res; 2003 Aug; 63(15):4507-15. PubMed ID: 12907624
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.
Charalambous A; Oks M; Nchinda G; Yamazaki S; Steinman RM
J Immunol; 2006 Dec; 177(12):8410-21. PubMed ID: 17142738
[TBL] [Abstract][Full Text] [Related]
10. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
12. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma.
Grube M; Moritz S; Obermann EC; Rezvani K; Mackensen A; Andreesen R; Holler E
Clin Cancer Res; 2007 Feb; 13(3):1053-60. PubMed ID: 17289902
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
[TBL] [Abstract][Full Text] [Related]
14. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
[TBL] [Abstract][Full Text] [Related]
15. The universal character of the tumor-associated antigen survivin.
Andersen MH; Svane IM; Becker JC; Straten PT
Clin Cancer Res; 2007 Oct; 13(20):5991-4. PubMed ID: 17947459
[TBL] [Abstract][Full Text] [Related]
16. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
17. Full-length dominant-negative survivin for cancer immunotherapy.
Pisarev V; Yu B; Salup R; Sherman S; Altieri DC; Gabrilovich DI
Clin Cancer Res; 2003 Dec; 9(17):6523-33. PubMed ID: 14695157
[TBL] [Abstract][Full Text] [Related]
18. T-cell responses to survivin in cancer patients undergoing radiation therapy.
Schaue D; Comin-Anduix B; Ribas A; Zhang L; Goodglick L; Sayre JW; Debucquoy A; Haustermans K; McBride WH
Clin Cancer Res; 2008 Aug; 14(15):4883-90. PubMed ID: 18676762
[TBL] [Abstract][Full Text] [Related]
19. Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells.
Naota H; Miyahara Y; Okumura S; Kuzushima K; Akatsuka Y; Hiasa A; Kitano S; Takahashi T; Yuta A; Majima Y; Shiku H
J Immunol Methods; 2006 Jul; 314(1-2):54-66. PubMed ID: 16828790
[TBL] [Abstract][Full Text] [Related]
20. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
